HUTCHMED (China) Limited (HK:0013) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
HUTCHMED (China) Limited has announced that its New Drug Application for the combination of ORPATHYS® and TAGRISSO® in treating lung cancer patients with MET amplification has been accepted for priority review in China. This marks a significant step for the company, as the combination aims to offer a chemotherapy-free, all-oral treatment option for patients with resistant non-small cell lung cancer. The acceptance also triggers a milestone payment from AstraZeneca, highlighting the potential impact of this innovative therapy on the lung cancer treatment landscape.
For further insights into HK:0013 stock, check out TipRanks’ Stock Analysis page.